EX-27

WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

 

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from
Circa Pharmaceuticals, Inc. consolidated financial statements for the
quarter ended September 30, 1994 and is qualified in its entirety by
reference to such financial statements.

       
                             
<PERIOD-TYPE>                   QTR-3
<FISCAL-YEAR-END>                          DEC-31-1994
<PERIOD-END>                               SEP-30-1994
<CASH>                                      11,770,285
<SECURITIES>                                25,822,621
<RECEIVABLES>                                  636,587
<ALLOWANCES>                                         0
<INVENTORY>                                  1,701,490
<CURRENT-ASSETS>                            50,428,673
<PP&E>                                      12,507,487
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                             106,333,313
<CURRENT-LIABILITIES>                        9,838,517
<BONDS>                                              0
<COMMON>                                       220,792
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                  76,071,541
<TOTAL-LIABILITY-AND-EQUITY>               106,333,313
<SALES>                                      1,320,178
<TOTAL-REVENUES>                             1,320,178
<CGS>                                          643,951
<TOTAL-COSTS>                                5,947,132
<OTHER-EXPENSES>                                18,555
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              3,708,904
<INCOME-TAX>                                   110,000
<INCOME-CONTINUING>                          3,598,904
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 3,598,904
<EPS-PRIMARY>                                      .17
<EPS-DILUTED>                                      .17
        

 

10-Q/A

                      UNITED STATES
              SECURITIES AND EXCHANGE COMMISSION
                  Washington, D.C. 20549

                        FORM 10-QA

        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
           OF THE SECURITIES EXCHANGE ACT OF 1934



For the quarterly period            Commission File Number 0-8049
ended September 30, 1994  


                      CIRCA PHARMACEUTICALS, INC.


Incorporated under the laws              11-1966265
of the State of New York                                          
                           (I.R.S. Employer Identification Number)



         33 RALPH AVENUE, COPIAGUE, NEW YORK 11726


             Telephone number (516) 842-8383




                      Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                     Yes               No      



                      The number of shares of Common Stock, par
value $.01 per share, outstanding were 21,711,912 as of October 28,
1994.

                                   SIGNATURES



        Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.


                                      CIRCA PHARMACEUTICALS, INC.



DATE:  November 2, 1994             /s/Melvin Sharoky, M.D.       
                         Melvin Sharoky, M.D., President 
                               and Chief Executive Officer




DATE:  November 2, 1994             /s/Thomas P. Rice             
                          Thomas P. Rice, Executive Vice President,
                          Chief Operating and Financial Officer